Oshen Holdings takes 16.6% stake in Mitorx Therapeutics
Published
Oshen Holdings SA entered Mitorx Therapeutics, a mitochondrial drug developer, with Early Series A2 shares giving it a 16.6% stake.
Raphbros Ltd entered with Early Series A2 shares representing a 1.0% stake.
Spika Invest Limited entered with Early Series A2 shares representing a 1.0% stake.
Nirph Africa Ltd entered with Early Series A1 shares representing a 0.3% stake.
The multiple corporate entries and increased share count suggest fresh funding. Filed on 9 March 2026 for the period 1 March 2025 to 1 March 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| New shareholder | OSHEN HOLDINGS SA | 2,106,926 | — | EARLY SERIES A2 SHARES 2,106,926 |
| New shareholder | RAPHBROS LTD | 131,682 | — | EARLY SERIES A2 SHARES 131,682 |
| New shareholder | SPIKA INVEST LIMITED | 121,147 | — | EARLY SERIES A2 SHARES 121,147 |
| New shareholder | NIRPH AFRICA LTD | 35,115 | — | EARLY SERIES A1 SHARES 35,115 |
| New shareholder | BIOPHARMA DRUG LICENSING GROUP SL | 5,000 | — | EARLY SERIES A2 SHARES 5,000 |
Current shareholders (12)
| Shareholder | Total shares | Share classes |
|---|---|---|
| OSHEN HOLDINGS SA | 2,106,926 | EARLY SERIES A2 SHARES 2,106,926 |
| UNIVERSITY OF EXETER | 885,700 | ORDINARY 885,700 |
| PRISM (GENERAL PARTNER) LIMITED | 454,063 | ORDINARY 454,063 |
| WCS NOMINEES LIMITED | 313,972 | ORDINARY 313,972 |
| SCIENCE ANGEL SYNDICATE NOMINEES LIMITED | 299,903 | ORDINARY 299,903 |
| LONGEVITYTECH.FUND A.S. | 266,700 | ORDINARY 266,700 |
| EMPIRICAL VENTURES BBI NOMINEES LIMITED | 241,390 | A1 ORDINARY 75,247 ORDINARY 166,143 |
| RAPHBROS LTD | 131,682 | EARLY SERIES A2 SHARES 131,682 |
| SPIKA INVEST LIMITED | 121,147 | EARLY SERIES A2 SHARES 121,147 |
| PANACEA VENTURES NOMINEES LTD | 40,255 | ORDINARY 40,255 |
| NIRPH AFRICA LTD | 35,115 | EARLY SERIES A1 SHARES 35,115 |
| BIOPHARMA DRUG LICENSING GROUP SL | 5,000 | EARLY SERIES A2 SHARES 5,000 |
Contact the editorial team at editorial@fundingspotter.com